Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2007

01.02.2007

Radio Frequency Ablation for Hepatocellular Carcinoma in Cirrhotic Patients: Prognostic Factors for Survival

verfasst von: Alfredo Guglielmi, Andrea Ruzzenente, Marco Sandri, Silvia Pachera, Corrado Pedrazzani, Sebastiano Tasselli, Calogero Iacono

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Radio frequency ablation (RFA) of hepatocellular carcinoma has proved to be useful in local control of tumor. A few data on survival after treatment are available in literature. The aim of the study was to evaluate factors related to survival and to identify different classes of risk after radio frequency ablation.

Methods

Ninety-eight cirrhotic patients with 145 hepatocellular carcinomas were treated with radio frequency ablation from January 1998 to May 2004. In 55 patients, cirrhosis was in Child-Pugh class A, and in 43, in class B. Tumor was single in 60 and multiple in 38; mean tumor number was 1.5 (range 1–3). Tumor size ranged from 1.5 to 6.0 cm, mean 3.8 cm. Mean follow up period was 24.9 months. Radio frequency ablation was performed with expandable type needle with percutaneous approach under real-time ultrasound guidance. For statistical analysis, univariate and multivariate analysis were performed.

Results

Complete ablation of the tumor was achieved in 85.5% of lesions. Survival, 1 and 3 years, was 76.7 and 36.6%, respectively. Univariate analysis showed that Cancer of the Liver Italian Program (CLIP) score, tumor growth pattern, α-fetoprotein level, and complete tumor necrosis, were factors significantly related to poor survival. Multivariate analysis identified that factors related to poor survival were α-fetoprotein level >100 ng/ml, Child-Pugh class B, and incomplete tumor necrosis with a hazard ratio of 4.0, 2.7, and 3.8, respectively. After complete ablation, median survival was 38 months in patients with Child-Pugh class A cirrhosis and α-fetoprotein level ≤100 ng/ml, 22 months for patient with Child-Pugh class B cirrhosis and α-fetoprotein ≤100 ng/ml, and 9 months for patient with Child-Pugh class A cirrhosis and α-fetoprotein >100 ng/ml (P < 0.01).

Conclusions

Complete necrosis and absence of residual tumor positively affect survival after RFA. In patients with Child-Pugh A cirrhosis and α-fetoprotein level ≤100 radio frequency, ablation have results, 55% after 3 years, that are comparable to those of surgical resection. Patients with Child-Pugh B cirrhosis and/or α-fetoprotein >100 ng/ml showed less satisfactory results, and in these patients, multimodality treatment or other treatments should be considered.
Literatur
1.
Zurück zum Zitat Bosch, F. X., Ribes, J., & Borras, J. (1999). Epidemiology of primary liver cancer. Seminars in Liver Disease, 19, 271–285.PubMed Bosch, F. X., Ribes, J., & Borras, J. (1999). Epidemiology of primary liver cancer. Seminars in Liver Disease, 19, 271–285.PubMed
2.
Zurück zum Zitat Bosch, F. X., Ribes, J., Diaz, M., & Cleries, R. (2004). Primary liver cancer: Worldwide incidence and trends. Gastroenterology, 127(5 Suppl 1), S5–S16, Nov.PubMedCrossRef Bosch, F. X., Ribes, J., Diaz, M., & Cleries, R. (2004). Primary liver cancer: Worldwide incidence and trends. Gastroenterology, 127(5 Suppl 1), S5–S16, Nov.PubMedCrossRef
3.
Zurück zum Zitat Yanaga, K. (2004). Current status of hepatic resection for hepatocellular carcinoma. Journal of Gastroenterology, 39(10), 919–926, Oct.PubMedCrossRef Yanaga, K. (2004). Current status of hepatic resection for hepatocellular carcinoma. Journal of Gastroenterology, 39(10), 919–926, Oct.PubMedCrossRef
4.
Zurück zum Zitat Carr, B. I. (2004). Hepatocellular carcinoma: Current management and future trends. Gastroenterology, 127(5 Suppl 1), S218–S224, Nov.PubMedCrossRef Carr, B. I. (2004). Hepatocellular carcinoma: Current management and future trends. Gastroenterology, 127(5 Suppl 1), S218–S224, Nov.PubMedCrossRef
5.
Zurück zum Zitat Fong, Y., Sun, R. L., Jarnagin, W., & Blumgart, L. H. (1999). An analysis of 412 cases of hepatocellular carcinoma at a Western center. Annals of Surgery, 229, 790–799.PubMedCrossRef Fong, Y., Sun, R. L., Jarnagin, W., & Blumgart, L. H. (1999). An analysis of 412 cases of hepatocellular carcinoma at a Western center. Annals of Surgery, 229, 790–799.PubMedCrossRef
6.
Zurück zum Zitat Llovet, J. M., Fuster, J., & Bruix, J. (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology, 30, 1434–1440.PubMedCrossRef Llovet, J. M., Fuster, J., & Bruix, J. (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology, 30, 1434–1440.PubMedCrossRef
7.
Zurück zum Zitat Poon, R. T., Fan, S. T., Lo, C. M., Ng, I. O., Liu, C. L., Lam, C. M., et al. (2001). Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Annals of Surgery, 234, 63–70.PubMedCrossRef Poon, R. T., Fan, S. T., Lo, C. M., Ng, I. O., Liu, C. L., Lam, C. M., et al. (2001). Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Annals of Surgery, 234, 63–70.PubMedCrossRef
8.
Zurück zum Zitat Bruix, J., & Llovet, J. M. (2002). Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 35(3), 519–524, Mar.PubMedCrossRef Bruix, J., & Llovet, J. M. (2002). Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 35(3), 519–524, Mar.PubMedCrossRef
9.
Zurück zum Zitat Camma, C., Di Marco, V., Orlando, A., Sandonato L., Casaril A., Parisi P., et al. (2005). Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): A prospective study. Journal of Hepatology, 42(4), 535–540, Apr.PubMedCrossRef Camma, C., Di Marco, V., Orlando, A., Sandonato L., Casaril A., Parisi P., et al. (2005). Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): A prospective study. Journal of Hepatology, 42(4), 535–540, Apr.PubMedCrossRef
10.
Zurück zum Zitat Montorsi, M., Santambrogio, R., Bianchi, P., Donadon, M., Moroni, E., Spinelli, A., et al. (2005). Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: A multivariate analysis. Journal of Gastrointestinal Surgery, 9(1), 62–67, Jan.PubMedCrossRef Montorsi, M., Santambrogio, R., Bianchi, P., Donadon, M., Moroni, E., Spinelli, A., et al. (2005). Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: A multivariate analysis. Journal of Gastrointestinal Surgery, 9(1), 62–67, Jan.PubMedCrossRef
11.
Zurück zum Zitat Vivarelli, M., Guglielmi, A., Ruzzenente, A., Cucchetti, A., Bellusci, R., Cordiano, C., et al. (2004). Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Annals of Surgery, 240(1), 102–107, Jul.PubMedCrossRef Vivarelli, M., Guglielmi, A., Ruzzenente, A., Cucchetti, A., Bellusci, R., Cordiano, C., et al. (2004). Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Annals of Surgery, 240(1), 102–107, Jul.PubMedCrossRef
12.
Zurück zum Zitat Pugh, R. N. H., Murray-Lyon, I. M., & Dawson, J. L. (1973). Transection of oesophagus for bleeding oesophageal varices. British Journal of Surgery, 60, 646–664.PubMedCrossRef Pugh, R. N. H., Murray-Lyon, I. M., & Dawson, J. L. (1973). Transection of oesophagus for bleeding oesophageal varices. British Journal of Surgery, 60, 646–664.PubMedCrossRef
13.
Zurück zum Zitat The Cancer of the Liver Italian Program (CLIP) Investigators. (1998). A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology, 28, 751–755.CrossRef The Cancer of the Liver Italian Program (CLIP) Investigators. (1998). A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology, 28, 751–755.CrossRef
14.
Zurück zum Zitat Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., et al. (2001). EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology, 35 (3), 421–430, Sep.PubMedCrossRef Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., et al. (2001). EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology, 35 (3), 421–430, Sep.PubMedCrossRef
15.
Zurück zum Zitat Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981). Reporting results of cancer treatment. Cancer, 47, 207–214.PubMedCrossRef Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981). Reporting results of cancer treatment. Cancer, 47, 207–214.PubMedCrossRef
16.
Zurück zum Zitat Rabe-Hesketh, S., & Everitt, B. S. A. (2003). Handbook of Statistical Analyses Using Stata (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC. Rabe-Hesketh, S., & Everitt, B. S. A. (2003). Handbook of Statistical Analyses Using Stata (3rd ed.). Boca Raton, FL: Chapman & Hall/CRC.
17.
Zurück zum Zitat Austin, P. C., & Tu, J. V. (2004). Bootstrap methods for developing predictive models. The American Statistician, 58(2), 131–137.CrossRef Austin, P. C., & Tu, J. V. (2004). Bootstrap methods for developing predictive models. The American Statistician, 58(2), 131–137.CrossRef
18.
Zurück zum Zitat May, S., & Hosmer, D. W. (1998). A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Analysis, 4, 109–120.PubMedCrossRef May, S., & Hosmer, D. W. (1998). A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Analysis, 4, 109–120.PubMedCrossRef
19.
Zurück zum Zitat Lencioni, R. A., Allgaier, H. P., Cioni, D., Olschewski, M., Deibert, P., Crocetti L., et al. (2003). Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology, 228, 235–240.PubMed Lencioni, R. A., Allgaier, H. P., Cioni, D., Olschewski, M., Deibert, P., Crocetti L., et al. (2003). Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology, 228, 235–240.PubMed
20.
Zurück zum Zitat Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., & Gazelle, G. S. (1999). Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection. Radiology, 210, 655–661.PubMed Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., & Gazelle, G. S. (1999). Small hepatocellular carcinoma: Treatment with radiofrequency ablation versus ethanol injection. Radiology, 210, 655–661.PubMed
21.
Zurück zum Zitat Guglielmi, A., Ruzzenente, A., Battocchia, A., Tonon, A., Fracastoro, G., & Cordiano, C. (2003). Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology, 50, 480–484.PubMed Guglielmi, A., Ruzzenente, A., Battocchia, A., Tonon, A., Fracastoro, G., & Cordiano, C. (2003). Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology, 50, 480–484.PubMed
22.
Zurück zum Zitat Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni F., Ierace T., Solbiati L., et al. (2000). Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology, 214(3), 761–768, Mar.PubMed Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni F., Ierace T., Solbiati L., et al. (2000). Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology, 214(3), 761–768, Mar.PubMed
23.
Zurück zum Zitat Poon, R. T., Ng, K. K., Lam, C. M., Ai, V., Yuen, J., & Fan, S. T. (2004). Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Archives of Surgery, 139(3), 281–287, Mar.PubMedCrossRef Poon, R. T., Ng, K. K., Lam, C. M., Ai, V., Yuen, J., & Fan, S. T. (2004). Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Archives of Surgery, 139(3), 281–287, Mar.PubMedCrossRef
24.
Zurück zum Zitat Rossi, S., Di Stasi, M., Buscarini, E., Quaretti P., Garbagnati F., Squassante L., et al. (1996). Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. American Journal of Roentgenology, 167, 759–768.PubMed Rossi, S., Di Stasi, M., Buscarini, E., Quaretti P., Garbagnati F., Squassante L., et al. (1996). Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. American Journal of Roentgenology, 167, 759–768.PubMed
25.
Zurück zum Zitat Sala, M., Llovet, J. M., Vilana, R., Bianchi L., Sole M., Ayuso C., et al. (2004). Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology, 40(6), 1352–1360, Dec.PubMedCrossRef Sala, M., Llovet, J. M., Vilana, R., Bianchi L., Sole M., Ayuso C., et al. (2004). Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology, 40(6), 1352–1360, Dec.PubMedCrossRef
26.
Zurück zum Zitat Tangkijvanich, P., Anukulkarnkusol, N., Suwangool, P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P., et al. (2000). Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels. Journal of Gastrointestinal Surgery, 31, 302–308. Tangkijvanich, P., Anukulkarnkusol, N., Suwangool, P., Lertmaharit S., Hanvivatvong O., Kullavanijaya P., et al. (2000). Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels. Journal of Gastrointestinal Surgery, 31, 302–308.
27.
Zurück zum Zitat Wayne, J. D., Lauwers, G. Y., Ikai, I., Doherty, D. A., Belghiti, J., Yamaoka Y., et al. (2002). Preoperative predictors of survival after resection of small hepatocellular carcinomas. Annals of Surgery, 235(5), 722–730, May.PubMedCrossRef Wayne, J. D., Lauwers, G. Y., Ikai, I., Doherty, D. A., Belghiti, J., Yamaoka Y., et al. (2002). Preoperative predictors of survival after resection of small hepatocellular carcinomas. Annals of Surgery, 235(5), 722–730, May.PubMedCrossRef
28.
Zurück zum Zitat Wildi, S., Pestalozzi, B. C., McCormack, L., & Clavien, P. A. (2004). Critical evaluation of the different staging systems for hepatocellular carcinoma. British Journal of Surgery, 91(4), 400–408, Apr.PubMedCrossRef Wildi, S., Pestalozzi, B. C., McCormack, L., & Clavien, P. A. (2004). Critical evaluation of the different staging systems for hepatocellular carcinoma. British Journal of Surgery, 91(4), 400–408, Apr.PubMedCrossRef
29.
Zurück zum Zitat The Cancer of the Liver Italian Program (CLIP) Investigators. (2000). Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology, 31, 840–845.CrossRef The Cancer of the Liver Italian Program (CLIP) Investigators. (2000). Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology, 31, 840–845.CrossRef
30.
Zurück zum Zitat Ueno, S., Tanabe, G., Sako, K., Hiwaki T., Hokotate H., Fukukura Y., et al. (2001). Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology, 34, 529–534.PubMedCrossRef Ueno, S., Tanabe, G., Sako, K., Hiwaki T., Hokotate H., Fukukura Y., et al. (2001). Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology, 34, 529–534.PubMedCrossRef
31.
Zurück zum Zitat Zhao, W. H., Ma, Z. M., Zhou, X. R., Feng, Y. Z., & Fang, B. S. (2002). Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World Journal of Gastroenterology, 8, 237–242.PubMed Zhao, W. H., Ma, Z. M., Zhou, X. R., Feng, Y. Z., & Fang, B. S. (2002). Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World Journal of Gastroenterology, 8, 237–242.PubMed
Metadaten
Titel
Radio Frequency Ablation for Hepatocellular Carcinoma in Cirrhotic Patients: Prognostic Factors for Survival
verfasst von
Alfredo Guglielmi
Andrea Ruzzenente
Marco Sandri
Silvia Pachera
Corrado Pedrazzani
Sebastiano Tasselli
Calogero Iacono
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2007
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-006-0082-y

Weitere Artikel der Ausgabe 2/2007

Journal of Gastrointestinal Surgery 2/2007 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.